TrialThe lancet. Diabetes & endocrinology2013

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.

Michael Roden et al.PubMed ↗Publisher ↗

No numbers read from the abstract.